Sanofi Joins with TB Alliance to Find New Treatments Against Tuberculosis
The French pharmaceutical company, Sanofi, recently announced an agreement with the Global Alliance for TB Drug Development (TB Alliance) to collaborate on the discovery and development of new TB drugs. Both companies will work to develop novel compounds in Sanofi’s library that have shown promise against the TB bacterium. The agreement includes in-depth research of lead compounds based upon identified chemical derivatives of natural products and chemical optimization of other series of compounds that have been identified as hits in high-throughput screening. Sanofi discovered rifampicin, one of the first-line antituberculosis drugs, in the early 1960s.
Date of Publication
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.